Which diabetes drug best protects your heart? 60,000-person study aims to find out.
NCT ID NCT07417618
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This large study looks at real-world data from 60,000 people with type 2 diabetes and obesity to compare four diabetes drugs—dulaglutide, semaglutide, tirzepatide, and sitagliptin—in preventing heart attacks, strokes, and death. Researchers are analyzing insurance claims to see which drug works best, both in people with and without existing heart disease. The goal is to guide doctors in choosing the most effective treatment for heart protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dulaglutide, semaglutide, tirzepatide, sitagliptin
- What this could lead to
- If successful, this could show which diabetes drug is best at preventing heart attacks and strokes in people with type 2 diabetes and obesity.
- What could go wrong
- This is an observational study using existing data, not a controlled experiment, so results may be less reliable. It also compares drugs already on the market, so no new treatment is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCVD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Two-Drug combo tip the scales against obesity?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?